Metalloproteinase dependent reduction of cell surface cluster determinants upon the induction of apoptosis

Magro,Albert; Magro,Alice; Shrestha,Sirish; Brundage,Kathy; Rankin,Gary

doi:10.3892/ijo.2014.2344

May-2014 Volume 44 Issue 5

Full Size Image

Cover Legend PDF

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2014 Volume 44 Issue 5

Full Size Image

Cover Legend PDF

Article

Metalloproteinase dependent reduction of cell surface cluster determinants upon the induction of apoptosis

Authors:
- Albert Magro
- Alice Magro
- Sirish Shrestha
- Kathy Brundage
- Gary Rankin
View Affiliations / Copyright

Affiliations: Department of Biology, Fairmont State University, Fairmont, WV, USA, Department of Statistics, West Virginia University, Morgantown, WV, USA, Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV, USA, Department of Pharmacology, Physiology and Toxicology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA
Pages: 1539-1550
|
Published online on: March 13, 2014

https://doi.org/10.3892/ijo.2014.2344
Expand metrics +

Abstract

LN18 glioblastoma cells were used as a model to examine changes in surface cluster determinants (CDs) as the cells undergo apoptosis. LN18 cells proceeding through apoptosis manifested a decrease in cell adhesion molecules, growth factor receptors and other surface proteins. Apoptosis was induced by MK886, a known FLAP and PPAR-α inhibitor, or staurosporine, a known inhibitor of protein kinases including protein kinase C (PKC). The detection and decrease of surface CDs were observed by flow cytometry using CD-specific primary antibodies followed by secondary antibodies conjugated to phycoerythrin. It was determined that there was an apoptotic induced decrease of α and β integrin determinants and the growth factor receptors EGFR and IGF1R. The MHC-1 cell surface marker HLA-ABC was also reduced in the apoptotic cells. The level of EGFR, IGF1R and detected α and β integrin determinants dropped dramatically. The degradation takes place in mid to late apoptosis. It was determined by real-time RT-PCR that the decrease in integrins, EGFR, IGF1R and MHC-1 determinants were not due to a reduction in transcription. Inhibitors of metalloproteinases blocked the apoptotic decrease in cell surface determinants indicating that metalloproteinases mediated the reduction in these CDs in a manner that can reduce growth and survival signals while stimulating the NK surveillance system. Overall, the data indicate that the final stages of the pharmacological induction of apoptosis, while proceeding to a full commitment to non-necrotic cell death, involves the degradation of integrin, insulin and epidermal growth factor receptors caused by a programmed dysregulation of the cell's metalloproteinases.

View Figures

View References

1.	Lockshin RA and Williams CM: Programmed cell death-II. Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths. J Insect Physiol. 10:643–649. 1964. View Article : Google Scholar
2.	Sulston J and Brenner S: The DNA of Caenorhabditis elegans. Genetics. 77:95–104. 1974.
3.	Sulston JE and Horvitz HR: Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol. 56:110–156. 1977. View Article : Google Scholar : PubMed/NCBI
4.	Jacobson MD, Weil M and Raff MC: Programmed cell death in animal development. Cell. 88:347–354. 1997. View Article : Google Scholar : PubMed/NCBI
5.	Horvitz HR: Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res. 59(Suppl 7): 1701–1706. 1999.PubMed/NCBI
6.	Li Y, Fengyi W, Sudeshna D, et al: Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci USA. 103:4952–4957. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Taddei ML, Giannoni E, Fiaschi T and Chiarugi P: Anoikis: an emerging hallmark in health and diseases. J Pathol. 226:380–393. 2012. View Article : Google Scholar : PubMed/NCBI
9.	Hirsch T, Marchetti P, Susin SA, et al: The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene. 15:1573–1581. 1997. View Article : Google Scholar
10.	Proskuryakov SY, Konoplyannikov A and Gabai VL: Necrosis: a specific form of programmed cell death. Exp Cell Res. 283:1–16. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Gilmore AP, Metcalfe AD, Romer LH and Streuli CH: Integrin-mediated survival signals regulate the apoptotic function of bax through its conformation and subcellular localization. J Cell Biol. 149:431–445. 2000. View Article : Google Scholar : PubMed/NCBI
12.	LeRoith D, Werner H, Beitner-Johnson D and Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 16:143–163. 1995. View Article : Google Scholar
13.	Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW and Burgessa AW: Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res. 284:31–53. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Adams TE, McKern NM and Ward CW: Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors. 22:89–95. 2004. View Article : Google Scholar : PubMed/NCBI
15.	van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM and Roovers RC: Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets. 9:748–760. 2009.PubMed/NCBI
16.	Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:239–257. 1972. View Article : Google Scholar
17.	Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI
18.	Ruoslahti E and Pierschbacher MD: New perspectives in cell adhesion: RGD and integrins. Science. 238:491–497. 1987. View Article : Google Scholar : PubMed/NCBI
19.	Ruoslahti E: Integrins. J Clin Invest. 87:1–5. 1991. View Article : Google Scholar
20.	Ruoslahti E and Reed JC: Anchorange independence, integrins, and apoptosis. Cell. 77:477–478. 1994. View Article : Google Scholar : PubMed/NCBI
21.	Frisch SM and Ruoslahti E: Integrins and anoikis. Curr Opin Cell Biol. 9:701–706. 1997. View Article : Google Scholar : PubMed/NCBI
22.	Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell. 3:17–22. 2003. View Article : Google Scholar
23.	Zhong X and Rescorla FJ: Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal. 24:393–401. 2012. View Article : Google Scholar : PubMed/NCBI
24.	Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Zahreddine H and Borden KL: Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 4:282013. View Article : Google Scholar
26.	Beier D, Schulz JP and Beier CP: Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer. 10:1282011. View Article : Google Scholar : PubMed/NCBI
27.	Zeiss CJ: The apoptosis-necrosis continuum: insights from genetically altered mice. Vet Pathol. 40:481–495. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Hacker G: The morphology of apoptosis. Cell Tissue Res. 301:5–17. 2000. View Article : Google Scholar
29.	Diserens AC, de Tribolet N, Martin-Achard A, et al: Characterization of an established human malignant glioma cell line: LN-18. Acta Neuorpathol. 53:21–28. 1981. View Article : Google Scholar : PubMed/NCBI
30.	Anderson KM, Seed T, Jajeh A, et al: An in vivo inhibitor of 5-lipoxygenase, MK886, at micormolar concentration induces apoptosis in U937 and CML cells. Anticancer Res. 16:2589–2599. 1966.PubMed/NCBI
31.	Ghosh J and Myers CE: Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA. 95:13182–13187. 1998. View Article : Google Scholar
32.	Ghosh J and Myers CE: Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun. 235:418–423. 1997. View Article : Google Scholar : PubMed/NCBI
33.	Tong WG, Ding XZ and Adrian TE: The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun. 296:942–948. 2002. View Article : Google Scholar : PubMed/NCBI
34.	Dixon RAF, Diehl RE, Opas E, et al: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 343:282–284. 1990. View Article : Google Scholar : PubMed/NCBI
35.	Miller DK, Gillard JW, Vickers PJ, et al: Identification and isolation of a membrane protein necessary for leukotriene production. Nature. 343:278–281. 1990. View Article : Google Scholar : PubMed/NCBI
36.	Ford-Hutchinson AW: FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol Sci. 12:68–70. 1991. View Article : Google Scholar : PubMed/NCBI
37.	Vegesna RV, Wu HL, Mong S and Crooke ST: Staurosporine inhibits protein kinase C and prevents phorbol ester-mediated leukotriene D4 receptor desensitization in RBL-1 cells. Mol Pharmacol. 33:537–542. 1998.
38.	Belmokhtar CA, Hillion J and Ségal-Bendirdjian E: Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene. 20:3354–3362. 2001. View Article : Google Scholar : PubMed/NCBI
39.	Kabir J, Lobo M and Zachary I: Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis. Biochem J. 367:145–155. 2002. View Article : Google Scholar
40.	Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 80:285–291. 1995. View Article : Google Scholar : PubMed/NCBI
41.	Hetz C, Vitte PA, Bombrun A, et al: Bax channel inhibitors prevent mitochondrion-mediated apoptosis and protect neurons in a model of global brain ischemia. J Biol Chem. 280:42960–42970. 2005. View Article : Google Scholar : PubMed/NCBI
42.	Narita M, Shimizu S, Ito T, et al: Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA. 95:14681–14686. 1998. View Article : Google Scholar : PubMed/NCBI
43.	Zamzami N, Marchetti P, Castedo M, et al: Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 182:367–377. 1995. View Article : Google Scholar : PubMed/NCBI
44.	Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
45.	Adrain C, Creagh EM and Martin SJ: Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 20:6627–6636. 1997. View Article : Google Scholar : PubMed/NCBI
46.	Hill MM, Adrain C, Duriez PJ, Creagh EM and Martin SJ: Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. EMBO J. 23:2134–2145. 2004. View Article : Google Scholar : PubMed/NCBI
47.	Zou H, Li Y, Liu X and Wang X: An APAF-1 cytochrome c multimeric complex is a function apoptosome that activates procaspase-9. J Biol Chem. 274:11549–11556. 1999. View Article : Google Scholar : PubMed/NCBI
48.	Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:33–42. 2000. View Article : Google Scholar : PubMed/NCBI
49.	Li P, Nijhawan D, Budihardjo I, et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
50.	McIlwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 5:a0086562013. View Article : Google Scholar
51.	Martin SJ and Green DR: Protease activation during apoptosis: death by a thousand cuts? Cell. 82:349–352. 1995. View Article : Google Scholar : PubMed/NCBI
52.	Earnshaw WC, Martins LM and Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev. 68:383–424. 1999.PubMed/NCBI
53.	Zhang JH and Xu M: DNA fragmentation in apoptosis. Cell Res. 10:205–211. 2000. View Article : Google Scholar
54.	Okayama H: Cell cycle control by anchorage signaling. Cell Signal. 24:1599–1609. 2012. View Article : Google Scholar : PubMed/NCBI
55.	Aplin AE, Howe A, Alahari SK and Juliano RL: Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev. 50:197–263. 1998.PubMed/NCBI
56.	Schwartz MA and Baron V: Interactions between mitogenic stimuli, or, a thousand and one connections. Curr Opin Cell Biol. 11:197–202. 1999. View Article : Google Scholar : PubMed/NCBI
57.	McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/ MEK/ERK and P13K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
58.	Chitnis MM, Yuen JS, Protheroe AS, Pollak M and Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
59.	Ivaska J and Heino J: Cooperation between integrins and growth factor receptors in signaling and endocytosis. Ann Rev Cell Dev Biol. 27:291–320. 2011. View Article : Google Scholar : PubMed/NCBI
60.	Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell. 91:439–442. 1997. View Article : Google Scholar : PubMed/NCBI
61.	Mott JD and Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 16:558–564. 2004. View Article : Google Scholar : PubMed/NCBI
62.	Massova I, Kotra LP, Fridman R and Mobashery S: Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 12:1075–1095. 1998.PubMed/NCBI
63.	Nagase H and Woessner JF Jr: Matrix metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
64.	Seiki M: Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 194:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
65.	Sohail A, Sun Q, Zhao H, Bernardo MM, Cho JA and Fridman R: MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev. 27:289–302. 2008. View Article : Google Scholar : PubMed/NCBI
66.	Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med. 5:258–289. 2008. View Article : Google Scholar
67.	Tang BL: ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol. 33:33–44. 2001. View Article : Google Scholar : PubMed/NCBI
68.	Kang T, Nagase H and Pei D: Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Cancer Res. 62:675–681. 2002.PubMed/NCBI
69.	Kang T, Zhao YG, Pei D, Sucic JF and Sang QX: Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites. J Biol Chem. 277:25583–25591. 2002. View Article : Google Scholar
70.	Stawowy P, Meyborg H, Stibenz D, et al: Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circ. 111:2820–2827. 2005. View Article : Google Scholar
71.	Dubois CM, Laprise M-H, Blanchette F, Gentry LE and Leduc R: Processing of transforming growth factor β1 precursor by human furin convertase. J Biol Chem. 270:10618–10624. 1995.
72.	Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F and Seidah NG: Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol. 158:305–316. 2001. View Article : Google Scholar : PubMed/NCBI
73.	Letterio JJ and Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol. 16:137–161. 1998. View Article : Google Scholar : PubMed/NCBI
74.	Mantel PY and Schmidt-Weber CB: Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol. 677:303–338. 2011. View Article : Google Scholar : PubMed/NCBI
75.	Bommireddy R and Doetschman T: TGFβ1 and T_reg cells: alliance for tolerance Trends. Mol Med. 11:492–501. 2007.
76.	Gomez GG and Kruse CA: Mechanisms of malignant glioma resistance and sources of immunosuppression. Gene Ther Mol Biol. 10:133–146. 2006.PubMed/NCBI
77.	Avril T, Vauleon E, Tanguy-Royer S, Mosser J and Quillien V: Mechanisms of immunomodulation in human glioblastoma. Immunotherapy. 3(Suppl 4): 42–44. 2011. View Article : Google Scholar : PubMed/NCBI
78.	Leitlein J, Aulwurm S, Waltereit R, et al: Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol. 166:7238–7243. 2001. View Article : Google Scholar : PubMed/NCBI
79.	Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G and Klein-Szanto AJ: Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res. 8:1740–1746. 2002.PubMed/NCBI
80.	Poli A, Kmiecik J, Domingues O, et al: NK cells in central nervous system disorders. J Immunol. 190:5355–5362. 2013. View Article : Google Scholar : PubMed/NCBI
81.	Lodoen MB and Lanier LL: Viral modulation of NK cell immunity. Nat Rev Microbiol. 3:59–69. 2005. View Article : Google Scholar : PubMed/NCBI
82.	Vivier E, Raulet DH, Moretta A, et al: Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
83.	Daga A, Bottino C, Castriconi R, Gangemi R and Ferrini S: New perspectives in glioma immunotherapy. Curr Pharm Des. 17:2439–2467. 2011. View Article : Google Scholar : PubMed/NCBI
84.	Hegi ME, Rajakannu P and Weller M: Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol. 25:774–779. 2012. View Article : Google Scholar : PubMed/NCBI
85.	Pala A, Karpel-Massler G, Kast RE, Wirtz CR and Halatsch ME: Epidermal to mesenchymal transition and failure of EGFR-targeted therapy in glioblastoma. Cancers. 4:523–530. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Metalloproteinase dependent reduction of cell surface cluster determinants upon the induction of apoptosis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

Figure 11

Figure 12

Related Articles